Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Merck
Harvard Business School
Johnson and Johnson
Cerilliant
Medtronic
Moodys
Baxter
Federal Trade Commission
Dow

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,034,239

« Back to Dashboard

Summary for Patent: 6,034,239
Title: Tricyclic compounds, their production and use
Abstract:A compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4, O or S in which R.sup.4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.
Inventor(s): Ohkawa; Shigenori (Osaka, JP), Uchikawa; Osamu (Hyogo, JP), Fukatsu; Kohji (Hyogo, JP), Miyamoto; Masaomi (Hyogo, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:08/812,168
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 6,034,239

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa ROZEREM ramelteon TABLET;ORAL 021782-001 Jul 22, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,034,239

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-051491Mar 08, 1996
Japan8-183667Jul 12, 1996
Japan9-029185Feb 13, 1997

Non-Orange Book US Patents Family Members for Patent 6,034,239

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,218,429 Tricyclic compounds, their production and use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,034,239

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 4358917 ➤ Sign Up
Japan 2884153 ➤ Sign Up
Japan H11152281 ➤ Sign Up
Japan H10287665 ➤ Sign Up
Hungary 224220 ➤ Sign Up
Hungary 9900616 ➤ Sign Up
Hong Kong 1087112 ➤ Sign Up
Spain 2175350 ➤ Sign Up
European Patent Office 1550655 ➤ Sign Up
European Patent Office 1199304 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Chinese Patent Office
Express Scripts
Fuji
Cerilliant
Accenture
Fish and Richardson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot